When will the patents on NORISODRINE AEROTROL expire, and when will NORISODRINE AEROTROL go generic?

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbott	NORISODRINE AEROTROL	isoproterenol hydrochloride	DISC;INHALATION	016814-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Get Started Free	⤷ Get Started Free				⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Norisodrine Aerotrol (isoproterenol sulfate) is an inhaled bronchodilator with a long history of use in treating bronchospasm associated with asthma and other respiratory conditions. This analysis examines the current market landscape and the patent protection surrounding Norisodrine Aerotrol, identifying key opportunities and potential challenges for investment and R&D.

What is the Current Market Status of Norisodrine Aerotrol?

Norisodrine Aerotrol is a racemic mixture of the beta-adrenergic agonist isoproterenol. It functions by stimulating beta-2 adrenergic receptors in the smooth muscle of the airways, leading to bronchodilation. Historically, it was a significant treatment for asthma and COPD. However, its use has declined considerably due to the development of more selective beta-2 agonists and inhaled corticosteroids, which offer improved efficacy and safety profiles.

Key Market Indicators

Primary Indication: Bronchodilator for relief of bronchospasm associated with asthma, bronchitis, and emphysema.
Administration Route: Inhalation via metered-dose inhaler (MDI).
Market Share: Severely diminished. Older generation bronchodilator, largely superseded by newer agents.
Competition: Dominated by short-acting beta-agonists (SABAs) like albuterol/salbutamol and long-acting beta-agonists (LABAs), as well as inhaled corticosteroids (ICS) and combination therapies.
Availability: While historically significant, Norisodrine Aerotrol is now a niche product with limited market presence in many developed countries. Its continued availability is often maintained by specific manufacturers for specific markets or patient populations who have historically relied on it or where cost is a primary consideration.
Regulatory Status: Approved by the U.S. Food and Drug Administration (FDA) and other regulatory bodies, but its therapeutic niche has shrunk.

The decline in Norisodrine Aerotrol's market share is attributed to several factors:

Selectivity: Isoproterenol is a non-selective beta-agonist, meaning it also stimulates beta-1 receptors. This can lead to cardiovascular side effects such as tachycardia, palpitations, and arrhythmias. Newer SABAs are more beta-2 selective, minimizing these side effects. [1]
Duration of Action: While providing rapid relief, its duration of action is comparable to or shorter than some newer SABAs, requiring more frequent dosing for sustained effect.
Availability of Superior Therapies: The development of ICS and fixed-dose combination inhalers (e.g., ICS/LABA) has provided more comprehensive and effective management strategies for chronic respiratory diseases, often with better safety profiles and convenience. [2]

Despite its diminished role, Norisodrine Aerotrol might retain a presence in specific therapeutic contexts:

Cost-Sensitive Markets: In regions with significant healthcare cost constraints, older, off-patent drugs like isoproterenol may remain a viable option.
Specific Patient Populations: Certain patients who have a long history of stable use and do not experience significant side effects may continue to use it.
Emergency Situations: Its rapid onset of action could still make it useful in acute, life-threatening bronchospasm situations, although this role is increasingly filled by nebulized albuterol.

What is the Patent Landscape for Norisodrine Aerotrol?

Norisodrine Aerotrol is based on isoproterenol sulfate, a compound discovered and patented decades ago. The original composition of matter patents for isoproterenol have long expired. Current patent activity, if any, would likely focus on specific formulations, manufacturing processes, delivery devices, or novel therapeutic uses.

Key Patent Considerations

Original Composition of Matter: Patents covering the isoproterenol molecule itself expired in the mid-20th century. This means the active pharmaceutical ingredient (API) is in the public domain.
Formulation Patents: Patents may exist for specific formulations of isoproterenol sulfate designed to improve stability, bioavailability, or delivery. This could include specific excipients, stabilizers, or suspension technologies.
Device Patents: If Norisodrine Aerotrol is delivered via a specific type of metered-dose inhaler (MDI), associated patents for the inhaler device or its specific components could be relevant. However, standard MDI technology is also largely off-patent.
Method of Use Patents: While less common for older drugs, patents might theoretically cover novel or specific methods of using isoproterenol for particular conditions or patient groups. These are generally difficult to enforce if prior art exists.
Manufacturing Process Patents: Patents may cover optimized or novel manufacturing processes for producing isoproterenol sulfate or its specific salt forms. These patents typically relate to the method of production rather than the substance itself.
Exclusivity Periods: For any newer formulations or delivery systems, any associated patent would define a period of market exclusivity. However, given the age of the API, finding significant new patent protection with a long runway is unlikely.

Example of Patent Filing Trends (Hypothetical):

A search of patent databases would likely reveal a concentration of patent filings related to isoproterenol in the mid-20th century. Post-2000 filings would be sparse and primarily related to incremental improvements or niche applications.

Patent Filing Year Range	Primary Patent Focus	Relevance to Norisodrine Aerotrol
1940s - 1960s	Composition of Matter, Early Formulations	Foundation of the drug
1970s - 1990s	Improved Formulations, Manufacturing Processes	Potential for specific versions
2000s - Present	Niche Formulations, Delivery Devices, Novel Uses	Limited impact on core product

Crucially, there are no active patents that grant market exclusivity for Norisodrine Aerotrol as a generic inhaled bronchodilator. Any company can manufacture and sell generic isoproterenol sulfate for inhalation, provided they meet regulatory requirements.

What are the Investment and R&D Opportunities?

Given the established patent landscape and market position of Norisodrine Aerotrol, direct investment in the current formulation is unlikely to yield significant returns. However, opportunities might exist in specific, narrowly defined areas.

Investment Scenarios

Generic Market Entry: Manufacturing and selling generic isoproterenol sulfate for inhalation. This would compete on price and target cost-sensitive markets or specific niche patient segments.
- Challenge: Low margins, intense competition from other generic bronchodilators, and a declining overall market.
- Opportunity: Potential for supplying markets where cost is the primary driver or where established supply chains exist.
Strategic Supply Agreements: Supplying isoproterenol sulfate API or finished product to existing distributors or formulators in regions where it remains in demand.
- Challenge: Dependence on third parties, limited growth potential.
- Opportunity: Stable, albeit low-growth, revenue stream.

R&D Opportunities

R&D opportunities for Norisodrine Aerotrol are extremely limited due to its age and the availability of superior alternatives. Any R&D would need to focus on highly specific, unmet needs that existing treatments do not address, or on overcoming its inherent limitations in a novel way.

Novel Delivery Systems (Highly Speculative): Developing a next-generation inhaler device that significantly improves lung deposition or reduces the systemic absorption of isoproterenol, thereby mitigating side effects.
- Challenge: High R&D costs, significant technical hurdles to overcome isoproterenol's inherent pharmacokinetic profile, and competition from advanced delivery systems for modern drugs. The therapeutic benefit might not justify the investment compared to developing new molecules.
- Feasibility: Low.
Combination Therapies (Unlikely): Investigating novel fixed-dose combinations of isoproterenol with other agents (e.g., anticholinergics or corticosteroids) for specific indications.
- Challenge: Isoproterenol's non-selective beta-agonist profile makes it a poor candidate for combination therapy compared to selective beta-2 agonists. The risk of additive side effects (especially cardiovascular) would be significant. Regulatory hurdles for a new combination product with an old API are also high.
- Feasibility: Very Low.
Niche Indications (Extremely Niche): Identifying highly specific, rare respiratory conditions or situations where isoproterenol's unique (though often suboptimal) profile might offer a benefit not met by other drugs. This would require extensive preclinical and clinical research.
- Challenge: Identifying such a niche is difficult, and the market size would likely be prohibitively small for commercial development.
- Feasibility: Extremely Low.

The fundamental challenge for Norisodrine Aerotrol is that it represents an obsolete therapeutic class. The medical community has largely moved past it due to clear advantages in efficacy, safety, and convenience offered by newer medications. Investment and R&D efforts are overwhelmingly directed towards novel targets, more selective mechanisms of action, and advanced therapeutic modalities.

What are the Regulatory Considerations?

Navigating the regulatory landscape for Norisodrine Aerotrol involves considerations related to its established market presence and its status as an older drug.

Regulatory Factors

FDA and EMA Approval: Norisodrine Aerotrol (isoproterenol sulfate for inhalation) has existing approvals from major regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Generic Drug Pathway: If a company intends to market a generic version of Norisodrine Aerotrol, they would typically follow the abbreviated new drug application (ANDA) pathway in the U.S. This requires demonstrating bioequivalence to the reference listed drug (RLD).
Manufacturing Standards: Manufacturers must adhere to current Good Manufacturing Practices (cGMP) for both the API and the finished drug product.
Labeling and Prescribing Information: The product labeling must accurately reflect the current understanding of its efficacy, safety, indications, contraindications, warnings, and precautions. This would necessitate detailing its role as a second-line or historical therapy and highlighting the risks of cardiovascular side effects due to its non-selective beta-agonist nature. [3]
Post-Market Surveillance: As with all drugs, post-market pharmacovigilance is required to monitor for adverse events.
Discontinuation and Supply: If a manufacturer ceases production, regulatory bodies may require notification and efforts to ensure continued supply if there are no other viable alternatives for specific patient populations.
Orphan Drug Designation: Highly unlikely to be applicable given its broad historical use and lack of novelty.

The primary regulatory hurdle for new entrants is not obtaining initial approval, but rather establishing bioequivalence and navigating the competitive landscape of generics and established branded products. For any novel R&D, the path would involve full new drug application (NDA) processes, which are considerably more arduous and expensive, especially for a drug with such a well-understood and largely superseded profile.

Key Takeaways

Norisodrine Aerotrol is a long-established bronchodilator whose market share has significantly declined due to the availability of more selective, safer, and effective alternatives.
The patent protection for the active pharmaceutical ingredient, isoproterenol sulfate, has long expired. Current patent activity, if any, is limited to niche formulations or manufacturing processes with minimal impact on the core product's market exclusivity.
Direct investment in the current formulation of Norisodrine Aerotrol is unlikely to be profitable due to low margins and a shrinking market. R&D opportunities are extremely limited and highly speculative, as the drug's inherent limitations and the advancement of respiratory therapeutics make it an unattractive candidate for significant innovation.
Regulatory considerations primarily involve generic approval pathways (e.g., ANDA) and adherence to cGMP. Any new development would face high hurdles given the drug's established, albeit diminished, profile.

Frequently Asked Questions

What is the primary reason for Norisodrine Aerotrol's reduced market presence? Norisodrine Aerotrol is a non-selective beta-agonist, leading to a higher incidence of cardiovascular side effects compared to newer, beta-2 selective bronchodilators.
Are there any active patents protecting Norisodrine Aerotrol as a drug? No, the original composition of matter patents for isoproterenol sulfate have long expired, making the active ingredient generic.
Could Norisodrine Aerotrol be repurposed for new indications? While theoretically possible, its non-selective mechanism and side effect profile make it an unlikely candidate for repurposing compared to drugs with more favorable pharmacological properties.
What is the cost advantage of Norisodrine Aerotrol compared to modern bronchodilators? As a generic drug with expired patents, Norisodrine Aerotrol would be significantly cheaper to manufacture than branded novel therapies, making it potentially viable in cost-sensitive markets.
Is there potential for a new R&D investment in developing an improved formulation of Norisodrine Aerotrol? The potential for significant return on investment in developing an improved formulation is very low, given the limited market, the drug's inherent pharmacological limitations, and the vast array of superior therapeutic options already available.

Citations

[1] Tashkin, D. P. (2000). Review of beta 2-adrenergic agonists in asthma therapy. Journal of Allergy and Clinical Immunology, 105(4), S470-S479.

[2] Global Initiative for Asthma. (2023). GINA Report, Global Strategy for Asthma Management and Prevention. https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-full-report.pdf

[3] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Orange Book website] (Note: A specific URL for a search would be ideal if available and stable, otherwise a general reference is appropriate).

NORISODRINE AEROTROL Drug Patent Profile

Which patents cover Norisodrine Aerotrol, and when can generic versions of Norisodrine Aerotrol launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Norisodrine Aerotrol

AI Deep Research

Questions you can ask:

Summary for NORISODRINE AEROTROL

US Patents and Regulatory Information for NORISODRINE AEROTROL

Norisodrine Aerotrol: Market Potential and Patent Landscape Analysis